No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
EGYPT – Pharma giant Novartis Egypt, with support from the Egyptian Vitreoretinal Society (EGVRS), has launched its nationwide campaign christened “Art of Vision” to raise public awareness of retinal diseases.…
Read More
SWITZERLAND — Novartis, a Swiss multinational pharmaceutical company has announced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis wants to spin off later this year.…
Read More
EGYPT – Sandoz Egypt Pharma, a division of the Novartis Group, and Ibnsina Pharma have signed a distribution and promotion agreement for the Sandoz over-the-counter (OTC) portfolio of products. Sandoz…
Read More
USA — Swiss pharma giant Novartis has sold five of its ophthalmic drugs to eye therapy company Harrow for a one-time payment of US$130 million, plus additional milestone payments of…
Read More
SWITZERLAND —Novartis and Medicines for Malaria Venture (MMV) have announced the decision to advance novel drug combination ganaplacide/lumefantrine into phase 3 development for the treatment of patients with acute uncomplicated…
Read More
SWITZERLAND — Pharmaceutical giant Novartis has signed a licensing agreement increasing access to vital leukemia treatment, the Medicines Patent Pool (MPP) has said, marking the first-ever such agreement for a…
Read More
IRELAND – Swiss pharmaceutical company, Novartis has announced plans to cut up to 400 jobs from its Dublin operations. The job cuts will occur over the next two years at…
Read More
MALAYSIA – Novartis Corporation (Malaysia) Sdn Bhd (NCSB) and Institut Jantung Negara (IJN) have formed the first ever scientific partnership to help Malaysians in improved cardiac care. The cooperation is…
Read More
EGYPT – Pharma giant Novartis Pharma Egypt and Cleopatra Hospitals Group (CHG), Egypt’s best provider of medical and healthcare services, have entered into a strategic partnership deal to provide the…
Read More
SWITZERLAND – Sandoz’s biologics license application (BLA) has been accepted by the US Food and Drug Administration (FDA) for a proposed ‘first-of-a-kind’ biosimilar natalizumab, developed by Polpharma Biologics, for the…
Read More